Article Summary
徐志成,秦卫军,杨力军,韩东辉,田春娟.干扰素诱导基因IFIT3对膀胱癌细胞生物学功能及化疗耐药性的影响[J].现代生物医学进展英文版,2021,(21):4011-4018.
干扰素诱导基因IFIT3对膀胱癌细胞生物学功能及化疗耐药性的影响
The Mechanism of Interferon-inducible Gene IFIT3 in Chemotherapy Resistance of Bladder Cancer
Received:March 15, 2021  Revised:April 10, 2021
DOI:10.13241/j.cnki.pmb.2021.21.003
中文关键词: 干扰素诱导基因  IFIT3  膀胱癌  化疗耐药性  热休克蛋白90
英文关键词: Interferon-inducible gene  IFIT3  Bladder cancer  Chemotherapy resistance  Heat shock protein 90
基金项目:国家自然科学基金面上项目(81772734)
Author NameAffiliationE-mail
徐志成 中国人民解放军空军军医大学第一附属医院泌尿外科 陕西 西安 710032 ZhichengXu1982@163.com 
秦卫军 中国人民解放军空军军医大学第一附属医院泌尿外科 陕西 西安 710032  
杨力军 中国人民解放军空军军医大学第一附属医院泌尿外科 陕西 西安 710032  
韩东辉 中国人民解放军空军军医大学第一附属医院泌尿外科 陕西 西安 710032  
田春娟 中国人民解放军空军军医大学第一附属医院泌尿外科 陕西 西安 710032  
Hits: 842
Download times: 440
中文摘要:
      摘要 目的:探讨干扰素诱导基因IFIT3在膀胱癌中的表达及对膀胱癌细胞生物学功能和化疗耐药性的影响。方法:本研究通过qRT-PCR或Western blot检测了30例膀胱移行细胞癌患者的肿瘤组织和配对正常癌旁组织标本以及人膀胱癌细胞系T24及人膀胱上皮永生化细胞SV-HUC-1中IFIT3的表达水平。通过浓度递增法构建顺铂(DDP)耐药T24细胞(T24/DDP),然后对细胞转染靶向IFIT3的siRNA(si-IFIT3)及阴性对照(si-NC)。将细胞分为4组,分别为T24-si-NC组、T24-si-IFIT3组、T24/DDP-si-NC组、T24/DDP-si-IFIT3组,通过MTT法检测细胞增殖,使用Annexin V-FITC/PI凋亡检测试剂盒检测细胞凋亡,使用Transwell法检测细胞侵袭能力。通过qRT-PCR或Western blot检测HSP90α(HSP90AA1)、MMP2、MMP9、Cleaved-caspase-3、Bcl-2和Bax的表达水平。结果:与配对癌旁组织和SV-HUC-1相比,膀胱癌组织和T24细胞中IFIT3的mRNA和蛋白表达水平显著升高(P<0.001)。与正常T24细胞相比,T24/DDP细胞中的IFIT3 mRNA和蛋白表达水平显著升高(P<0.001)。与T24/DDP-si-NC组相比,T24/DDP-si-IFIT3组的IC50值和侵袭细胞数显著降低,而细胞凋亡率显著升高(P<0.05)。与T24/DDP-si-NC组相比,T24/DDP-si-IFIT3组的Bcl-2、MMP2和MMP9蛋白相对表达量显著降低,而Bax和Cleaved-caspase-3蛋白相对表达量显著升高(P<0.05)。String数据库显示,IFIT3与HSP90AA1基因存在互作关系。与T24/DDP-si-NC组相比,T24/DDP-si-IFIT3组的HSP90α(HSP90AA1)表达水平显著降低(P<0.05)。结论:下调IFIT3的表达可抑制膀胱癌细胞的增殖和侵袭,并促进细胞凋亡,下调IFIT3可部分通过抑制HSP90α (HSP90AA1)的表达来降低膀胱癌细胞对顺铂的耐药性。
英文摘要:
      ABSTRACT Objective: To investigate the expression of interferon-induced gene IFIT3 in bladder cancer and its influence on the biological function and chemotherapy resistance of bladder cancer cells. Methods: In this study, IFIT3 expression in 30 bladder transitional cell carcinoma patients' tumor tissues and paired normal adjacent tissue specimens as well as human bladder cancer cell line T24 and human bladder epithelial immortalized cells SV-HUC-1 were detected by qRT-PCR or Western blot. The cisplatin (DDP) resistant T24 cells (T24/DDP) were constructed by the concentration increasing method, and then the cells were transfected with siRNA targeting IFIT3 (si-IFIT3) and a negative control (si-NC). The cells were divided into 4 groups, namely T24-si-NC group, T24-si-IFIT3 group, T24/DDP-si-NC group, T24/DDP-si-IFIT3 group. MTT method was used to detect cell proliferation, Annexin V-FITC/PI apoptosis detection kit was used to detect cell apoptosis, and Transwell method was used to detect cell invasion ability. The expressions of HSP90α (HSP90AA1), MMP2, MMP9, Cleaved-caspase-3, Bcl-2 and Bax were detected by qRT-PCR or Western blot. Results: Compared with paired adjacent tissues and SV-HUC-1, the expression levels of IFIT3 mRNA or protein in bladder cancer tissues and T24 cells were significantly increased (P<0.001). Compared with normal T24 cells, IFIT3 mRNA and protein expression levels in T24/DDP cells were significantly increased(P<0.001). Compared with the T24/DDP-si-NC group, the IC50 value and the number of invaded cells in the T24/DDP-si-IFIT3 group were significantly reduced, while the apoptosis rate was significantly increased(P<0.05). Compared with the T24/DDP-si-NC group, the relative expression of Bcl-2, MMP2 and MMP9 protein in the T24/DDP-si-IFIT3 group was significantly reduced, while the relative expression of Bax and Cleaved-caspase-3 protein was significantly increased(P<0.05). The String database showed that there was an interaction between IFIT3 and HSP90AA1 genes. Compared with the T24/DDP-si-NC group, the expression level of HSP90α (HSP90AA1) in the T24/DDP-si-IFIT3 group was significantly lower (P<0.05). Conclusion: Down-regulating the expression of IFIT3 can inhibit the proliferation and invasion of bladder cancer cells, and promote cell apoptosis. Down-regulating the expression of IFIT3 can reduce the resistance of bladder cancer cells to cisplatin in part by inhibiting the expression of HSP90α (HSP90AA1).
View Full Text   View/Add Comment  Download reader
Close